Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and ...

Elevated immune and neuronal injury markers in MSM with HIV and PrEP suggest lifestyle factors, beyond HIV, drive persistent ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A brain abscess is a rare but life-threatening infection. Learn how advances in imaging, surgery, and diagnostics are ...

Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my most recent analysis.

The developer of the CNSide technology invested over $300 million in this core technology and after a year of detailed analysis and preparation by our team and key consultants, our enthusiasm ...

Cerebrospinal fluid (CSF) analysis is a common diagnostic tool in the investigation of neurological presentations. Whether its routine use after every brain magnetic resonance imaging (MRI) is ...

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a ...

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1 ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an analysis of RHHBY stock now.

Dementia prevalence in India is rising, with experts emphasizing comprehensive evaluations, reversible causes, and global therapy advances.